A Snapshot of Transdermal and Topical Drug Delivery Research in Canada

Roohnikan, Mahdi; Laszlo, Elise; Babity, Samuel

doi:10.3390/pharmaceutics11060256

Cited by 28 publications

(16 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These observations are considered as a support of the hypothesis that the increased permeability of PDMS films is attributed to the unique pore shape created by PEG or PG within the PDMS film. 2 Higuchi dissolution constant at steady state flux (ks), estimated time (ts) of steady state and determination coefficient (R 2 ), 3 PEG values of the calculated fit to the Equation (1), when steady state flux was achieved. Numbers were bolded for better data comparison.…”

Section: Water Transport-permeability Swelling and Erosion Of Pdms Fmentioning

confidence: 99%

“…The transdermal drug administration route remains a constant focus of pharmaceutical research [1,2]. Transdermal patches are formulations applied to the skin for local or systemic drug delivery.…”

Section: Introductionmentioning

confidence: 99%

“…Pearson's correlation coefficients factor (r p ), p < 0.05 denotes significance,2 Higuchi dissolution constant at steady state flux (k s ), estimated time (t s ) of steady state and determination coefficient (R 2 ),3 PEG values of the calculated fit to the Equation (1), when steady state flux was achieved. Numbers were bolded for better data comparison.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Controlled Drug Release by the Pore Structure in Polydimethylsiloxane Transdermal Patches

et al. 2020

View full text Add to dashboard Cite

The use of polydimethylsiloxanes (PDMS) as a drug carrier in transdermal adhesive patches is limited and there is insufficient data on the polymer structure and diffusivity, especially when additives modify the matrix. PDMS films with liquid additives (10% w/w): silicone oil (SO), polyoxyethylene glycol (PEG) or propylene glycol (PG) were prepared and indomethacin (IND; 5% w/w) was incorporated as a model active substance. The microstructure of the PDMS matrix and its permeability to water was investigated and correlated to the kinetics of the in-vitro IND release from the film. Three microscopic techniques were used to characterize in detail the microstructure of PDMS films: scanning electron microscopy, fluorescent microscopy and atomic force microscopy. PDMS films with hydrophilic PEG or PG showed different two-phase structures. A two-fold increase in steady-state flux of IND and increased water transport in the presence of PEG was attributed to the pore-like channels created by this polar solvent in the PDMS matrix. This effect was not observed in the films with PG, where only discontinuous droplet-like structures were visible. All additives significantly changed the tensile parameters of the films but the effects were not very pronounced.

show abstract

Section: Water Transport-permeability Swelling and Erosion Of Pdms Fmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Controlled Drug Release by the Pore Structure in Polydimethylsiloxane Transdermal Patches

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It regards with the encapsulation of the therapeutic protein in multilayered, lipid-based submicronvesicles (Altum_Pharmaceuticals_Inc. ;Roohnikan et al, 2019). These vesicles have complex structures that include a variety of compartments into which drug molecules can be integrated, and the emulsion is completed with other excipients typical of a topic formulation.…”

Section: Protein-loaded Liposomes In the Clinicmentioning

confidence: 99%

Nanosized Delivery Systems for Therapeutic Proteins: Clinically Validated Technologies and Advanced Development Strategies

Moncalvo

Espinoza

Cellesi

2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The impact of protein therapeutics in healthcare is steadily increasing, due to advancements in the field of biotechnology and a deeper understanding of several pathologies. However, their safety and efficacy are often limited by instability, short half-life and immunogenicity. Nanodelivery systems are currently being investigated for overcoming these limitations and include covalent attachment of biocompatible polymers (PEG and other synthetic or naturally derived macromolecules) as well as protein nanoencapsulation in colloidal systems (liposomes and other lipid or polymeric nanocarriers). Such strategies have the potential to develop next-generation protein therapeutics. Herein, we review recent research progresses on these nanodelivery approaches, as well as future directions and challenges.

show abstract

“…The transdermal therapy has the potential to bypass the first pass metabolism, as well as decreases gastrointestinal side effects and, thereby, improve the safety and patient adherence. However, the transdermal delivery systems are not suitable for drugs with large molecular weight or which causes skin sensitization or irritation [24]. In general, the physicochemical properties of drug molecules, including aqueous solubility (>1 mg/mL), molecular size (<500 Daltons), lipophilicity (log P of 1–3), melting point (<200 °C), and dose (<25 mg/day) are considered, while developing transdermal drug delivery systems [25].…”

Section: Introductionmentioning

confidence: 99%

Effective Therapeutic Delivery and Bioavailability Enhancement of Pioglitazone Using Drug in Adhesive Transdermal Patch

et al. 2019

View full text Add to dashboard Cite

The administration of pioglitazone as an oral therapy is restricted due to various challenges. The aim of the current investigation was to evaluate the suitability of pioglitazone in adhesive transdermal patch as an alternative delivery system, in order to improve therapeutic delivery. Drug in adhesive pioglitazone (2% w/w) transdermal patch were optimized for drug release, suitable adhesive, and skin permeation enhancer. The selected patch was examined for drug-loading capacity and the patch with greater pioglitazone (6% w/w) was evaluated in rat models. The release of pioglitazone was influenced by the tested adhesive and was shown to be significantly higher (p < 0.001) with patch, prepared using Duro-Tak 87-2516. The ex vivo permeation results substantiate the release data as a greater transdermal flux (15.67 ± 2.35 µg/cm2/h) was demonstrated in patch fabricated with Duro-Tak 87-2516. Skin penetration enhancers promoted the ex vivo transdermal delivery of pioglitazone, and was ~2 folds (p < 0.0001) higher with propylene glycol, as compared to patch without enhancer. The maximum solubility of pioglitazone in Duro-Tak 87-2516 was found to be 6% w/w. Increasing the drug content in patch enhanced the transdermal flux and was highest when the pioglitazone level was 6% w/w (72.68 ± 5.76 µg/cm2/h). In vivo pharmacokinetic data demonstrate that the AUC0-α in transdermal application (13,506.51 ± 1649.92 ng·h/mL) was ~2 times higher (p < 0.0001) as compared to oral dosage form. In conclusion, the promising results observed here signifies that developed patch could be a viable alternative for oral therapy of pioglitazone.

show abstract

A Snapshot of Transdermal and Topical Drug Delivery Research in Canada

Cited by 28 publications

References 98 publications

Controlled Drug Release by the Pore Structure in Polydimethylsiloxane Transdermal Patches

Controlled Drug Release by the Pore Structure in Polydimethylsiloxane Transdermal Patches

Nanosized Delivery Systems for Therapeutic Proteins: Clinically Validated Technologies and Advanced Development Strategies

Effective Therapeutic Delivery and Bioavailability Enhancement of Pioglitazone Using Drug in Adhesive Transdermal Patch

Contact Info

Product

Resources

About